Episode 65

On this week’s episode of Biotech Hangout, hosts Brad Loncar, Chris Garabedian, Tim Opler, Dawn Bell and guest host Brian Skorney talk the latest in industry news. They discuss the first FDA approved Alzheimer’s drug to slow cognitive decline plus the subsequent retirement of Esai’s CEO /Alzheimer’s lead. Several other headlines this week including Eli Lilly’s Versanis acquisition, ADC Therapeutics pausing trial enrollment, Illumina’s fine and BeiGene and Novartis terminating their agreement. The hosts also talk about China-related news including the FDA planning to import more doses of chemotherapy from China and four of the top 10 global pharma license deals this year have come from China. They also discuss ophthalmology news from Astellas, 4D Molecular Therapeutics and Tenpoint Therapeutics. Other news covered this week includes the role of AI in drug development following Nvidia’s investment in Recursion, Apogee and Sagimet’s IPOs targeting, Viridian data and Avrobio considering M&A. *This episode aired on July 14, 2023*